A Protein Identified to Make Mesothelioma More Susceptible Towards Treatment
In most types of cancer treatments, doctors heavily rely on chemotherapy as their traditional line of treatment.
Mesothelioma happens to be a rare form of cancer which is caused due to the exposure of asbestos related products for over a long period of time.
As malignant mesothelioma has proved resistant
to the above protocol, patients have to face a grim prognosis.
As per an article published on the
mesothelioma.net, the final respite in the mesothelioma treatment has come from
a California based drug company, focusing on a specific protein to make
mesothelioma more susceptible to chemotherapy.
The company has recently announced success in
the first three phases of its clinical trials.
Also Read: 5 Known Reasons Why You Require A Mesothelioma Attorney
How Therapeutic Protein Blocks Nutrient to Mesothelioma Cells
The name of the company is Polaris Group which
has long been exploring a therapeutic protein called pegargiminase.
It works by blocking the supply of arginine to
malignant mesothelioma cells.
As you might be aware of Arginine is mainly
required for the survival of cells which is often needed in higher amounts in
cancer cells.
The researchers continue to explore if their
therapy can be able to create such a condition where malignant cells could lead
to stress along with altered gene expression and cell death without affecting
the normal and healthy functioning of cells.
John Bomalaski, who's the EVP of the company
says, “Preclinical data revealed various biochemical mechanisms that provide
compelling rationales for combining pegargiminase with other agents, and we are
exploring these potential synergies in our global clinical trial program.” he
said.
Survival Rates Tend to Increase In Malignant Mesothelioma Cases
The Polaris Group while exploring their
strategy to affect malignant cells has announced that phase 3 clinical trial
for mesothelioma treatment (ADI-PEG 20) has been successful.
After conducting the above research, the
company is looking forward to apply to the U.S. Food and Drug Administration
(FDA) for marketing approval next year.
Please note that the successful mesothelioma
trials were specifically carried out in some countries including the United
States. Due to their successful research, the company is planning to pursue its
marketing goal early in 2023.
Also Read: Immunotherapy: Best Treatment Option In the Dynamic Immuno-Oncology (IO) Market
Comments
Post a Comment